J. Polák

发表

Lack of benefit from semi‐annual screening for cancer of the lung: Follow‐up report of a randomized controlled trial on a population of high‐risk males in czechoslovakia

D. M. Parkin, M. Khlat, J. Erban, 1990, International journal of cancer.

Lung cancer detection results of a randomized prospective study in Czechoslovakia

J Polák, A Kubík, J. Polák, 1986, Cancer.

Percutaneous thin needle biopsy of malignant and nonmalignant thoracic lesions.

J. Polák, A. Kubík, 1989, Radiologia diagnostica.

From cryptic chromosomal lesions to pathologically relevant genes: Integration of SNP‐array with gene expression profiling in myelodysplastic syndrome with normal karyotype

Z. Zemanová, J. Březinová, K. Michalová, 2012, Genes, chromosomes & cancer.

High level of full‐length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

D. Mikulenková, J. Březinová, K. Michalová, 2015, European journal of haematology.

Location of the BCR/ABL Fusion Genes on Both Chromosomes 9q34 in Ph Negative Chronic Myeloid Leukemia

Z. Zemanová, J. Březinová, K. Michalová, 2002, Leukemia & lymphoma.

P230 BCR/ABL protein may be associated with an acute leukaemia phenotype

H. Klamová, G. Saglio, Z. Zemanová, 1998, British journal of haematology.

Real-time quantitative PCR (RQ-PCR) detection of minimal residual disease (MRD) by optimized WT1 assay to enhance risk stratification in acute myeloid leukemia (AML): A European leukemia net study [Abstract]

R. Hills, S. Schnittger, C. Preudhomme, 2007 .

Type J CBFβ/MYH11 Transcript in the M4Eo Subtype of Acute Myeloid Leukemia

Z. Zemanová, K. Michalová, J. Čermák, 2003 .

Molecular Diagnosis of Philadelphia-Positive Leukemias

C. Haškovec, J. Polák, 1999 .

Cereblon and Its Role in the Treatment of Multiple Myeloma by Lenalidomide or Pomalidomide

O. Fuchs, J. Polák, A. Kostečka, 2014 .

Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs.

H. Klamová, J. Moravcová, J. Schwarz, 2012, Blood cells, molecules & diseases.

Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.

D. Mikulenková, I. Marinov, A. Vítek, 2013, Neoplasma.

Using Quantitative Assessment of the Wilms Tumor 1 Gene Expression in Residual Disease Monitoring in Patients with Acute Myeloid Leukemia

J. Čermák, J. Schwarz, J. Polák, 2006 .

Multiple forms of cathepsin b in human lung cancer

J. Polak, J. Procházka, E. Křepela, 1995, International journal of cancer.

N-terminally truncated WT1 variant (sWT1) is expressed at very low levels in acute myeloid leukemia and advanced phases of chronic myeloid leukemia.

H. Klamová, J. Moravcová, J. Schwarz, 2012, Leukemia research.

An accelerrated-phase CML patient with e19a2 junction of BCR/ABL gene - the first case of transplanted CML with micro bcr

P. Cetkovský, C. Haškovec, V. Koza, 2000, Bone Marrow Transplantation.

Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression.

J. Schwarz, C. Haškovec, J. Marková, 2012, Experimental and therapeutic medicine.

Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis

M. Trněný, A. Vítek, P. Cetkovský, 2013, Clinical transplantation.

CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.

H. Klamová, Z. Zemanová, J. Moravcová, 2005, Leukemia research.